ODT

Odonate Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.29
-0.46
-3.12%
Opening 12:47 10/30 EDT
OPEN
14.75
PREV CLOSE
14.75
HIGH
14.95
LOW
14.22
VOLUME
107.24K
TURNOVER
--
52 WEEK HIGH
46.50
52 WEEK LOW
12.56
MARKET CAP
550.53M
P/E (TTM)
-3.6514
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Odonate Therapeutics (NASDAQ:ODT) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 2m ago
Odonate Therapeutics EPS in-line
Odonate Therapeutics (ODT): Q3 GAAP EPS of -$0.93 in-line.Cash of $188.3MPress Release
Seekingalpha · 2d ago
Odonate Therapeutics Q3 EPS $(0.93) Down From $(0.88) YoY
Odonate Therapeutics (NASDAQ:ODT) reported quarterly losses of $(0.93) per share. This is a 5.68 percent decrease over losses of $(0.88) per share from the same period last year.
Benzinga · 2d ago
New Strong Sell Stocks for October 21st
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Zacks · 10/21 11:36
Insiders Not Scared By Upcoming Risks - September 2020 Insider Update
Tracking insider purchases is an overlooked but very informative strategy. It can provide undervalued stocks in the market and can make assumptions for future market returns.September's number of insider purchases was close to the historical average, indicating that insiders are not scared from upcoming risks such as the election and COVID-19.Insiders are particularly buying stocks in the industrials sector recently.This monthly update also provides a list of the top 10 insider purchases by market cap and the top 10 insider purchases by value purchased.
Seekingalpha · 10/11 13:00
Results of CONTESSA, a Phase 3 Study of Tesetaxel in the Treatment of Patients with Metastatic Breast Cancer, to Be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
The results of CONTESSA, a Phase 3 study of tesetaxel in the treatment of patients with metastatic breast cancer, have been selected for an oral presentation at the 2020 SABCS, to be held virtually December 8-11, 2020.
Business Wire · 10/05 13:30
Odonate Therapeutics Reports Results Of CONTESSA, A Phase 3 Study Of Tesetaxel In Treatment Of Patients With Metastatic Breast Cancer, To Be Presented At The 2020 San Antonio Breast Cancer Symposium
Results of CONTESSA, a Phase 3 Study of Tesetaxel in the Treatment of Patients with Metastatic Breast Cancer, to Be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) The results of CONTESSA, a Phase 3
Benzinga · 10/05 12:35
These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each.
Seekingalpha · 10/03 20:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ODT. Analyze the recent business situations of Odonate Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ODT stock price target is 35.00 with a high estimate of 50.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 30.98M
% Owned: 80.32%
Shares Outstanding: 38.53M
TypeInstitutionsShares
Increased
34
744.38K
New
20
183.60K
Decreased
32
1.02M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.86%
Pharmaceuticals & Medical Research
-1.29%
Key Executives
Chairman/Chief Executive Officer/Director
Kevin Tang
Chairman/Chief Executive Officer/Director
kevin Tang
Chief Financial Officer
Michael Hearne
Chief Operating Officer
John Lemkey
Other
Joseph O'Connell
Director
Robert Rosen
Independent Director
Aaron Davis
Independent Director
Laura Douglass
Independent Director
Craig Johnson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ODT
Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Odonate Therapeutics Inc stock information, including NASDAQ:ODT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ODT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ODT stock methods without spending real money on the virtual paper trading platform.